BCL2 and neoplasm: An increase in the intensity of the TS1, anti-Ki67, and anti-Bcl-2 staining per cell was also observed in tumour cells treated with177Lu-DOTA-Tyr3-octreotate (Figures 1, 2, 3, and 4).